O	0	8	Clinical
O	9	16	utility
O	17	19	of
O	20	23	the
O	24	34	additional
O	35	38	use
O	39	41	of
B-intervention	42	46	blue
I-intervention	47	50	dye
I-intervention	51	54	for
I-intervention	55	66	indocyanine
I-intervention	67	72	green
O	73	76	for
O	77	85	sentinel
O	86	90	node
O	91	97	biopsy
O	98	100	in
O	101	107	breast
O	108	114	cancer
O	114	115	.

O	116	127	Indocyanine
O	128	133	green
O	134	135	(
O	135	138	ICG
O	138	139	)
O	140	142	is
O	143	149	widely
O	150	154	used
O	155	157	as
O	158	159	a
O	160	166	tracer
O	167	169	in
O	170	178	sentinel
O	179	184	lymph
O	185	189	node
O	190	196	biopsy
O	197	198	(
O	198	202	SLNB
O	202	203	)
O	204	206	of
O	207	215	patients
O	216	220	with
O	221	227	breast
O	228	234	cancer
O	234	235	.

O	236	243	Whether
O	244	248	SLNB
O	249	260	performance
O	261	264	can
O	265	267	be
O	268	276	improved
O	277	279	by
O	280	293	supplementing
O	294	297	ICG
O	298	302	with
O	303	312	methylene
O	313	317	blue
O	318	321	dye
O	322	329	remains
O	330	343	controversial
O	343	344	.

O	345	349	This
O	350	355	study
O	356	364	compared
O	365	368	the
O	369	380	performance
O	381	383	of
O	384	388	SLNB
O	389	393	when
O	394	397	ICG
O	398	401	was
O	402	406	used
O	407	412	alone
O	413	415	or
O	416	420	with
O	421	425	blue
O	426	429	dye
O	429	430	.

B-eligibility	431	442	Consecutive
I-eligibility	443	451	patients
I-eligibility	452	456	with
I-eligibility	457	459	T1
I-eligibility	459	460	-
I-eligibility	460	461	3
I-eligibility	462	469	primary
I-eligibility	470	476	breast
I-eligibility	477	483	cancer
O	484	486	at
O	487	490	our
O	491	499	hospital
O	500	504	were
O	505	514	recruited
O	515	519	into
O	520	523	our
O	524	529	study
O	530	533	and
O	534	544	randomized
O	545	547	to
O	548	555	undergo
B-control	556	560	SLNB
I-control	561	565	with
I-control	566	569	ICG
I-control	570	575	alone
O	576	577	(
O	577	578	n
O	579	580	=
B-control-participants	581	583	62
O	583	584	)
O	585	587	or
O	588	592	with
O	593	596	the
O	597	608	combination
O	609	611	of
O	612	615	ICG
O	616	619	and
O	620	624	blue
O	625	628	dye
O	629	630	(
O	630	631	n
O	632	633	=
B-intervention-participants	634	636	65
O	636	637	)
O	637	638	.

O	639	641	We
O	642	650	compared
O	651	654	the
O	655	658	two
O	659	666	methods
O	667	669	in
O	670	675	terms
O	676	678	of
O	679	693	identification
O	694	698	rate
O	698	699	,
O	700	706	number
O	707	710	and
O	711	720	detection
O	721	725	time
O	726	728	of
O	729	737	sentinel
O	738	743	lymph
O	744	749	nodes
O	750	751	(
O	751	755	SLNs
O	755	756	)
O	757	764	removed
O	764	765	.

B-outcome	766	769	SLN
I-outcome	770	784	identification
I-outcome	785	789	rate
O	790	794	were
O	795	802	similar
O	803	805	in
O	806	809	the
O	810	817	absence
O	818	819	(
B-cv-bin-percent	819	821	95
I-cv-bin-percent	821	822	.
I-cv-bin-percent	822	823	2
I-cv-bin-percent	823	824	%
O	824	825	)
O	826	828	or
O	829	837	presence
O	838	840	of
O	841	845	blue
O	846	849	dye
O	850	851	(
B-iv-bin-percent	851	853	98
I-iv-bin-percent	853	854	.
I-iv-bin-percent	854	855	5
I-iv-bin-percent	855	856	%
O	856	857	,
O	858	859	P
O	860	861	=
O	862	863	0
O	863	864	.
O	864	867	578
O	867	868	)
O	869	872	but
O	873	886	significantly
O	886	887	,
O	888	892	more
B-outcome	893	900	average
I-outcome	901	906	nodes
I-outcome	907	911	were
I-outcome	912	919	removed
O	920	924	when
O	925	929	blue
O	930	933	dye
O	934	937	was
O	938	942	used
O	943	944	(
B-iv-cont-mean	944	945	3
I-iv-cont-mean	945	946	.
I-iv-cont-mean	946	947	8
O	948	949	±
B-iv-cont-sd	950	951	1
I-iv-cont-sd	951	952	.
I-iv-cont-sd	952	953	5
O	954	960	versus
B-cv-cont-mean	961	962	2
I-cv-cont-mean	962	963	.
I-cv-cont-mean	963	964	7
O	965	966	±
B-cv-cont-sd	967	968	1
I-cv-cont-sd	968	969	.
I-cv-cont-sd	969	970	2
O	970	971	,
O	972	973	P
O	974	975	=
O	976	977	0
O	977	978	.
O	978	981	000
O	981	982	)
O	982	983	,
O	984	987	and
O	988	991	the
B-outcome	992	999	average
I-outcome	1000	1004	time
I-outcome	1005	1008	for
I-outcome	1009	1018	detecting
I-outcome	1019	1023	each
I-outcome	1024	1027	SLN
O	1028	1031	was
O	1032	1045	significantly
O	1046	1053	shorter
O	1054	1055	(
B-iv-cont-mean	1055	1056	3
I-iv-cont-mean	1056	1057	.
I-iv-cont-mean	1057	1059	91
O	1060	1061	±
B-iv-cont-sd	1062	1063	1
I-iv-cont-sd	1063	1064	.
I-iv-cont-sd	1064	1066	87
O	1067	1073	versus
B-cv-cont-mean	1074	1075	5
I-cv-cont-mean	1075	1076	.
I-cv-cont-mean	1076	1078	65
O	1079	1080	±
B-cv-cont-sd	1081	1082	2
I-cv-cont-sd	1082	1083	.
I-cv-cont-sd	1083	1085	95
I-cv-cont-sd	1086	1089	min
O	1089	1090	;
O	1091	1092	P
O	1093	1094	=
O	1095	1096	0
O	1096	1097	.
O	1097	1100	000
O	1100	1101	)
O	1101	1102	.

O	1103	1105	No
O	1106	1113	patient
O	1114	1116	in
O	1117	1120	the
O	1121	1126	study
O	1127	1138	experienced
O	1139	1145	severe
B-outcome	1146	1153	adverse
I-outcome	1154	1163	reactions
I-outcome	1164	1166	or
I-outcome	1167	1180	complications
O	1180	1181	.

B-outcome	1182	1192	Recurrence
I-outcome	1193	1195	of
I-outcome	1196	1204	axillary
I-outcome	1205	1209	node
O	1210	1213	was
O	1214	1222	detected
O	1223	1225	in
B-cv-bin-abs	1226	1229	one
O	1230	1237	patient
O	1238	1239	(
B-cv-bin-percent	1239	1240	1
I-cv-bin-percent	1240	1241	.
I-cv-bin-percent	1241	1242	6
I-cv-bin-percent	1242	1243	%
O	1243	1244	)
O	1245	1250	using
O	1251	1254	ICG
O	1255	1260	alone
O	1261	1264	but
B-iv-bin-abs	1265	1268	not
O	1269	1271	in
O	1272	1275	any
O	1276	1284	patients
O	1285	1290	using
O	1291	1294	ICG
O	1295	1298	and
O	1299	1303	blue
O	1304	1307	dye
O	1307	1308	.

O	1309	1312	The
O	1313	1323	efficiency
O	1324	1327	and
O	1328	1339	sensitivity
O	1340	1342	of
O	1343	1347	SLNB
O	1348	1351	can
O	1352	1354	be
O	1355	1363	improved
O	1364	1366	by
O	1367	1376	combining
O	1377	1380	ICG
O	1381	1385	with
O	1386	1390	blue
O	1391	1394	dye
O	1394	1395	.
